Last updated: August 11, 2026
Crisaborole is a nonsteroidal topical phosphodiesterase-4 inhibitor marketed in the United States as Eucrisa. Pfizer acquired the product through its $5.2 billion acquisition of Anacor Pharmaceuticals in 2016. Eucrisa generated rapid early growth after its 2016 approval, supported by demand for a steroid-free treatment for mild-to-moderate atopic dermatitis. Its commercial position has since weakened as branded topical competitors expanded, payer controls increased, and generic-entry risk moved closer.
The product’s value rests on three factors: its established pediatric label, nonsteroidal profile, and use in chronic atopic dermatitis. Its constraints are a narrow approved indication, topical tolerability complaints such as burning or stinging, relatively high branded pricing, and competition from topical calcineurin inhibitors, topical JAK inhibitors, topical PDE4 competitors, and emerging biologic therapies.
What is crisaborole and how does Eucrisa work?
Crisaborole is a small-molecule topical PDE4 inhibitor formulated as a 2% ointment. PDE4 inhibition reduces inflammatory signaling associated with atopic dermatitis. Eucrisa is applied twice daily to affected areas.
The FDA initially approved Eucrisa in December 2016 for the topical treatment of mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and older. In March 2020, the FDA expanded the label to include patients aged 3 months and older.[1]
FDA regulatory profile
| Attribute |
Crisaborole / Eucrisa |
| Active ingredient |
Crisaborole |
| Strength |
2% |
| Dosage form |
Topical ointment |
| FDA application |
NDA 207695 |
| Initial approval |
December 14, 2016 |
| Current pediatric label |
Patients aged 3 months and older |
| Indication |
Mild-to-moderate atopic dermatitis |
| Administration |
Topical, generally twice daily |
| Drug class |
PDE4 inhibitor |
| Biosimilar pathway |
Not applicable; crisaborole is a small molecule |
The expanded infant indication materially improved the product’s addressable population. It also strengthened Eucrisa’s position in an age group where physicians and parents often seek steroid-sparing options.
How has the financial trajectory of Eucrisa developed?
Eucrisa achieved a strong launch relative to many specialty dermatology products. Pfizer reported approximately $127 million in worldwide revenue in 2017, its first full commercial year. Revenue increased to about $238 million in 2018, $310 million in 2019, and $396 million in 2020.[2-5]
| Year |
Reported Eucrisa revenue |
Commercial development |
| 2016 |
Launch year |
FDA approval in December |
| 2017 |
Approximately $127 million |
Initial uptake in dermatology and pediatrics |
| 2018 |
Approximately $238 million |
Wider payer and physician adoption |
| 2019 |
Approximately $310 million |
Continued prescription growth |
| 2020 |
Approximately $396 million |
Pediatric label expansion to age 3 months |
| 2021 onward |
Not consistently disclosed as a standalone product line |
Greater portfolio-level reporting and competitive pressure |
Eucrisa’s revenue trajectory reflected several favorable launch characteristics:
- Atopic dermatitis has a large chronic patient population.
- Many patients and prescribers prefer to limit long-term topical corticosteroid use.
- Eucrisa offered a branded nonsteroidal option before the arrival of several newer topical agents.
- The label covered both adult and pediatric patients.
- The product fit dermatology and primary-care prescribing channels.
Revenue growth was not driven solely by higher patient volume. Pricing, formulary placement, specialty-pharmacy distribution, and the mix of commercially insured patients also affected reported sales.
What drove the early revenue expansion?
The 2017-2020 period benefited from a relatively open nonsteroidal topical market. Protopic and Elidel were established alternatives, but both had older brand histories and more restrictive perceptions around use. Eucrisa was positioned as a newer branded option with a distinct mechanism and a broad age indication.
The 2020 pediatric expansion improved the product’s commercial narrative, although the timing coincided with reduced physician visits and prescription disruption during the COVID-19 pandemic. The label expansion was strategically important but did not eliminate the product’s pricing and tolerability challenges.
How large is the market opportunity for crisaborole?
Atopic dermatitis is a large, recurrent market with demand across primary care, dermatology, pediatrics, and allergy practices. The commercial opportunity is segmented by disease severity:
| Segment |
Typical treatment role for crisaborole |
| Mild disease |
Potential first-line or steroid-sparing topical treatment |
| Moderate disease |
Adjunct or alternative to topical corticosteroids and calcineurin inhibitors |
| Severe disease |
Limited role; systemic or advanced targeted therapy often required |
| Infants and young children |
Important steroid-sparing use case |
| Maintenance therapy |
Potential use during recurring or lower-severity disease |
Crisaborole is most exposed to the mild-to-moderate segment. It does not compete directly across the entire atopic dermatitis market because moderate-to-severe patients may progress to biologics, oral JAK inhibitors, or other systemic treatments.
The relevant market is therefore narrower than the total atopic dermatitis market. Eucrisa’s addressable population is large, but its revenue potential is limited by treatment step edits, lower use in severe disease, and the availability of inexpensive topical corticosteroids.
How does crisaborole compare with competing atopic dermatitis drugs?
Crisaborole competes against both low-cost established therapies and premium branded medicines.
| Product or class |
Mechanism |
Main competitive effect on Eucrisa |
| Topical corticosteroids |
Broad anti-inflammatory activity |
Low-cost first-line pressure |
| Tacrolimus and pimecrolimus |
Topical calcineurin inhibition |
Established steroid-sparing alternatives |
| Ruxolitinib cream |
Topical JAK inhibition |
Premium branded competitor for mild-to-moderate disease |
| Roflumilast cream |
Topical PDE4 inhibition |
Mechanistic and therapeutic competition |
| Tapinarof cream |
AhR agonist |
Expands nonsteroidal topical competition |
| Dupilumab |
IL-4/IL-13 pathway inhibition |
Reduces topical-only treatment in moderate-to-severe disease |
| Tralokinumab |
IL-13 inhibition |
Competes in systemic treatment segments |
| Oral JAK inhibitors |
JAK inhibition |
Compete in advanced disease |
Eucrisa’s strongest differentiator is its long-standing pediatric and nonsteroidal positioning. Its weakest competitive attribute is the patient experience. Application-site burning and stinging can reduce persistence, particularly in children with active skin-barrier disruption.
How does crisaborole compare with topical ruxolitinib?
Topical ruxolitinib cream has a different mechanism and a more recent branded profile. It may be preferred for patients who need a stronger anti-inflammatory response or who do not respond to older topical options. Eucrisa retains an advantage in market familiarity and pediatric duration of use, but ruxolitinib has increased promotional and formulary competition in nonsteroidal topical therapy.
How does crisaborole compare with topical corticosteroids?
Corticosteroids remain the principal price competitor. Generic corticosteroids are inexpensive, widely available, and familiar to prescribers. Eucrisa is more likely to be used when a clinician wants a steroid-sparing regimen, when treatment involves sensitive areas, or when repeated disease recurrence creates concern about cumulative corticosteroid exposure.
What patents protect crisaborole and when does Eucrisa lose exclusivity?
Crisaborole was developed by Anacor and became part of Pfizer’s dermatology portfolio through the 2016 acquisition. The principal U.S. patent estate is based on composition-of-matter and related pharmaceutical patent families covering crisaborole and its topical use. Pfizer’s acquisition documents identified crisaborole as Anacor’s lead commercial asset and a central component of the transaction valuation.[6]
The commercial exclusivity assessment is more complex than a single patent date:
| Protection category |
Relevance |
| Composition-of-matter patents |
Primary protection for the active ingredient |
| Formulation patents |
Potential protection for the 2% ointment and excipient system |
| Method-of-use patents |
Potential coverage for treating atopic dermatitis |
| Regulatory exclusivity |
FDA exclusivity attached to the original approval and pediatric studies |
| Orange Book listings |
Define patents that an ANDA applicant must address |
| Patent-term adjustment |
May extend an issued patent beyond the ordinary 20-year calculation |
| Patent-term extension |
Could affect the listed expiry if granted |
The key commercial risk is a generic crisaborole 2% ointment entering after the relevant Orange Book patents and regulatory protections expire or after a settlement permits launch. Because crisaborole is a small molecule, generic manufacturers can use the abbreviated new drug application pathway. Biosimilar rules do not apply.
What is the Orange Book status of Eucrisa?
Eucrisa’s listed patents and regulatory exclusivities must be assessed through the FDA Orange Book and the current NDA record. The core patent estate has been approaching the late-2020s exclusivity window, making formulation and use patents commercially relevant even if the earliest composition claims have limited remaining life.[7]
The principal business implication is that the product’s value has shifted from long-duration exclusivity to lifecycle management. Any remaining patent protection must be evaluated against:
- Whether the patent is listed for the approved 2% ointment;
- Whether the claims cover the commercial formulation rather than only a broad compound;
- Whether an ANDA applicant can certify non-infringement or invalidity;
- Whether Pfizer or its commercial partner has filed an infringement action;
- Whether settlement terms establish an earlier authorized or licensed generic launch.
Are generic manufacturers challenging crisaborole through Paragraph IV filings?
Crisaborole is vulnerable to Paragraph IV challenges because it is a commercially established topical small molecule with a defined formulation and substantial historical revenue. An ANDA applicant may challenge listed patents by asserting that a patent is invalid, unenforceable, or not infringed.
A Paragraph IV filing can create:
- Patent litigation in federal district court;
- A potential 30-month stay of FDA approval under the Hatch-Waxman framework;
- Settlement negotiations involving an agreed generic-launch date;
- A licensed or authorized-generic arrangement;
- Loss of branded pricing before full patent expiry if an early entrant receives market access.
No biosimilar litigation is relevant to Eucrisa. The principal entry threat is conventional generic competition.
The commercial impact of a first generic would likely be significant. Topical dermatology products can experience rapid substitution once pharmacy benefit managers establish generic formulary preference. The erosion rate would depend on the number of approved ANDAs, state substitution rules, payer contracting, and whether Pfizer launches an authorized generic.
What formulation and manufacturing barriers protect crisaborole?
Crisaborole has a relatively manageable manufacturing profile because it is a synthetic small molecule in an ointment dosage form. The main barriers are commercial and regulatory rather than highly complex biologic manufacturing.
Potential barriers include:
- Demonstrating pharmaceutical equivalence to the reference ointment;
- Matching active-ingredient concentration and dosage form;
- Establishing bioequivalence under FDA requirements for topical products;
- Reproducing drug release and skin-permeation characteristics;
- Controlling particle size, suspension uniformity, and product stability;
- Obtaining suitable manufacturing capacity for topical semisolids;
- Meeting dermatological tolerability and container-closure requirements.
These barriers can delay generic approval, but they generally do not create the durable manufacturing moat associated with monoclonal antibodies, sterile injectables, or complex inhaled products.
What licensing deals and corporate transactions affect crisaborole?
The defining transaction was Pfizer’s acquisition of Anacor Pharmaceuticals in 2016. Pfizer agreed to acquire Anacor for approximately $5.2 billion, including assumed debt, giving Pfizer control of Eucrisa before the product’s FDA approval.[6]
The transaction implied a high valuation for a pre-launch dermatology asset. Its economic logic depended on:
- Rapid uptake in atopic dermatitis;
- Expansion into pediatric use;
- Durable branded pricing;
- Potential international commercialization;
- Lifecycle management around nonsteroidal topical therapy.
The deal also concentrated commercial risk in one product. Eucrisa’s performance was initially strong, but its long-term return depended on maintaining differentiation against inexpensive topical steroids and a growing group of branded nonsteroidal products.
What litigation and settlement issues affect Eucrisa?
The main legal exposure is Hatch-Waxman litigation arising from ANDA filings. The relevant issues are likely to include patent validity, claim construction, formulation scope, and whether a generic product practices listed claims.
Settlement economics are especially important for Eucrisa because the product is a topical medicine with potentially fast generic substitution. A settlement could preserve some branded revenue while allowing an agreed generic launch before the final patent expiry. The value of such a settlement would depend on the number of permitted entrants and the launch date.
There is no biologic exclusivity dispute comparable to those affecting products such as Dupixent. Eucrisa’s litigation profile is instead tied to ordinary small-molecule patent enforcement and FDA generic approval.
What generic launch scenarios exist for crisaborole?
| Scenario |
Likely commercial effect |
| No generic before final patent expiry |
Pfizer retains branded pricing longer |
| One authorized generic |
Faster price erosion but greater control over substitution |
| One independent generic |
Meaningful payer pressure and volume migration |
| Multiple generic entrants |
Rapid price compression and substantial branded share loss |
| Early settlement launch |
Partial erosion before patent expiry |
| Formulation dispute |
Potential delay or narrow generic entry |
The most likely long-term outcome for an established topical small molecule is a substantial decline in branded revenue after generic entry. Eucrisa’s residual value would then depend on pediatric familiarity, physician loyalty, supply reliability, and any commercial agreement supporting an authorized generic.
What is the geographic coverage and international market outlook?
Eucrisa’s strongest commercial base has been the United States, where Pfizer controlled the brand and benefited from a large prescription market and established payer infrastructure. International opportunities depend on country-specific approvals, reimbursement, local dermatology practice, and patent status.
Geographic risks include:
- Earlier generic entry outside the United States;
- Different pediatric labeling requirements;
- Lower reimbursement for branded topical products;
- Local preference for corticosteroids or calcineurin inhibitors;
- Separate patent and regulatory exclusivity calendars;
- Distributor and licensing arrangements that reduce net revenue.
The U.S. market remains the principal driver of product economics. International sales are less likely to offset a major U.S. generic event unless the brand has strong local reimbursement and limited competition.
How strong is the crisaborole patent estate?
The patent estate is commercially meaningful but no longer comparable to that of a newly launched protected asset. Its strengths are the approved product’s established formulation, long regulatory history, and potential Orange Book leverage. Its weaknesses are the approaching late-life exclusivity period, the small-molecule generic pathway, and the availability of alternative topical products.
| Strength |
Weakness |
| Approved 2% ointment with substantial use history |
Small-molecule ANDA pathway |
| Broad pediatric labeling |
High generic substitution potential |
| Established brand recognition |
Burning and stinging may reduce persistence |
| Potential formulation and use claims |
Competitive nonsteroidal topical pipeline |
| Large chronic disease population |
Low-cost corticosteroid alternatives |
What is the commercial outlook for crisaborole?
Eucrisa is likely to remain a relevant branded dermatology product while it retains meaningful formulary access and pediatric differentiation. Its growth ceiling is limited by competition from lower-cost therapies and newer branded agents. The product’s financial trajectory is more likely to follow a mature-brand pattern than a second high-growth launch cycle.
The main value inflection points are:
- Confirmation of current Orange Book patent expiry dates;
- Paragraph IV activity and ANDA approvals;
- Any settlement permitting early generic entry;
- Changes in Pfizer’s commercialization strategy;
- Formulary tier movement;
- Adoption of competing topical PDE4, JAK, and AhR therapies;
- Continued pediatric prescribing and maintenance use.
Key Takeaways
- Crisaborole is a topical PDE4 inhibitor marketed as Eucrisa for mild-to-moderate atopic dermatitis.
- FDA approval occurred in December 2016, with pediatric expansion to patients aged 3 months and older in 2020.
- Pfizer reported revenue growth from approximately $127 million in 2017 to approximately $396 million in 2020.
- The product’s commercial strengths are its nonsteroidal profile, pediatric label, and established prescriber base.
- Its main weaknesses are branded pricing, application-site burning or stinging, generic corticosteroid competition, and newer nonsteroidal products.
- Crisaborole is exposed to conventional generic competition, not biosimilar competition.
- The core patent estate is approaching the late-2020s exclusivity period, making Paragraph IV activity and settlement terms central to valuation.
- A first generic would likely produce substantial price and market-share erosion because pharmacy substitution is common in topical medicines.
- Eucrisa’s future value depends more on lifecycle management, pediatric positioning, and payer access than on broad market expansion.
FAQs About Crisaborole Market Dynamics
What was the peak annual revenue of Eucrisa?
Pfizer publicly reported approximately $396 million in Eucrisa revenue in 2020. Later Pfizer disclosures did not consistently present Eucrisa as a standalone product line.
Is crisaborole a steroid?
No. Crisaborole is a nonsteroidal topical PDE4 inhibitor.
Can crisaborole be used in infants?
Yes. The FDA-approved label covers patients aged 3 months and older.
Will generic crisaborole be cheaper than Eucrisa?
Generic crisaborole is expected to be priced below the branded product, although the magnitude of savings will depend on the number of entrants, payer contracting, and whether an authorized generic is launched.
Does crisaborole compete with Dupixent?
Yes, but the products occupy different treatment segments. Crisaborole is a topical treatment for mild-to-moderate disease, while Dupixent is an injectable biologic used primarily in moderate-to-severe atopic dermatitis and related inflammatory diseases.
References
- U.S. Food and Drug Administration. (2020). FDA approves expanded age range for Eucrisa (crisaborole) ointment.
- Pfizer Inc. (2017). 2017 annual report.
- Pfizer Inc. (2018). 2018 annual report.
- Pfizer Inc. (2019). 2019 annual report.
- Pfizer Inc. (2020). 2020 annual report.
- Pfizer Inc. (2016). Pfizer to acquire Anacor Pharmaceuticals.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
